The stock of AIM ImmunoTech Inc (AIM) has seen a -6.59% decrease in the past week, with a -4.76% drop in the past month, and a -25.93% decrease in the past quarter. The volatility ratio for the week is 9.43%, and the volatility levels for the past 30 days are at 9.71% for AIM. The simple moving average for the past 20 days is -6.03% for AIM’s stock, with a -35.14% simple moving average for the past 200 days.
Is It Worth Investing in AIM ImmunoTech Inc (AMEX: AIM) Right Now?
Additionally, the 36-month beta value for AIM is -0.30. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AIM is 59.62M and currently, short sellers hold a 1.06% ratio of that float. The average trading volume of AIM on January 31, 2025 was 640.06K shares.
AIM) stock’s latest price update
AIM ImmunoTech Inc (AMEX: AIM) has experienced a decline in its stock price by -0.50 compared to its previous closing price of 0.20. However, the company has seen a fall of -6.59% in its stock price over the last five trading days. globenewswire.com reported 2025-01-28 that NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE A PROSPECTUS OR OFFERING MEMORANDUM OR AN OFFER FOR SALE OR SUBSCRIPTION IN RESPECT OF ANY SECURITIES IN THE COMPANY.
AIM Trading at -4.83% from the 50-Day Moving Average
After a stumble in the market that brought AIM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.74% of loss for the given period.
Volatility was left at 9.71%, however, over the last 30 days, the volatility rate increased by 9.43%, as shares surge +1.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.31% lower at present.
During the last 5 trading sessions, AIM fell by -6.59%, which changed the moving average for the period of 200-days by -58.75% in comparison to the 20-day moving average, which settled at $0.2128. In addition, AIM ImmunoTech Inc saw 1.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AIM starting from Equels Thomas K, who purchase 20,000 shares at the price of $0.21 back on Nov 21 ’24. After this action, Equels Thomas K now owns 1,657,968 shares of AIM ImmunoTech Inc, valued at $4,240 using the latest closing price.
MITCHELL WILLIAM M, the Director of AIM ImmunoTech Inc, sale 4,580 shares at $0.19 during a trade that took place back on Dec 19 ’24, which means that MITCHELL WILLIAM M is holding 118,549 shares at $884 based on the most recent closing price.
Stock Fundamentals for AIM
Current profitability levels for the company are sitting at:
- -146.88 for the present operating margin
- 0.2 for the gross margin
The net margin for AIM ImmunoTech Inc stands at -125.94. The total capital return value is set at -8.0. Equity return is now at value -187.58, with -115.46 for asset returns.
Based on AIM ImmunoTech Inc (AIM), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -6.08. The debt to equity ratio resting at 1.17. The interest coverage ratio of the stock is -25.67.
Currently, EBITDA for the company is -31.68 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 84.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.75.
Conclusion
In conclusion, AIM ImmunoTech Inc (AIM) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
